The company, however, is optimistic that its sales in the domestic market this fiscal will be “slightly better” than last fiscal when sales had dropped by 23.90 per cent compared to 2019-20.
SMIPL, which had shut its plant for three weeks from April 28 due to oxygen supply constraints, is now coordinating with group firm Maruti Suzuki to address the issue, particularly those of its critical vendors, having resumed production from May 17.
“Because of the COVID-19, starting from last year our project is slightly delayed. Originally we were expecting more progress in these two years but because of COVID-19 the market hasn’t grown as expected… Earlier we had planned to enhance production capacity up to one million in this year but physically it is impossible in terms of number of sales,” newly appointed SMIPL Company Head Satoshi Uchida told PTI in an interview.
He further said, “We will be delayed by one year to one-and-a-half years. Three years ago we reached 7 lakh annual capacity. So as per the original plan we were supposed to reach one million (this year). So we have to invest to the current factory to reach one million production level but this year we cannot reach one million.”
Uchida was responding to a query on how the pandemic has impacted the company’s future investment plans in India.
While asserting that the company is bullish on the Indian market in the mid to long term, he said “in the short term we are obliged to delay current investment schedule”.
He, however, did not elaborate on the investment for the capacity ramp up to 10 lakh units.
In 2020-21, SMIPL’s production was down 24.87 per cent at 6,00,056 units as compared to 7,98,711 units in 2019-20.
On the current market condition and sales prospects for the ongoing fiscal, SMIPL Vice-President, Sales, Marketing and After Sales, Devashish Handa said, “This financial year we are looking forward to doing better than what we did last year, provided the pandemic situation is also not as severe as what we are going through right now.”
In 2020-21, SMIPL sold 521,474 units in the domestic market, down 23.90 per cent from 6,85,219 units sold in 2019-20
Demand side is not much of an issue but it has more to do with the disruptions in the supply chain because of the lockdowns. Also with the oxygen issue, the company has had to make whatever it can, he added.
“We always had a situation with the order book higher than what we could supply. It was more to do with supply limitation. We could not make as much as the demand,” Handa said.
Commenting on the oxygen supply issue, Uchida said the company had to close its factory for three weeks shutdown but has resumed operations since May 17.
“What we experienced was that more than our in-house need of oxygen, which is relatively low, it was more critical in our supply chain in some critical vendors. To that effect, there is some support that has been mobilised…We are now coordinating with Maruti, which is actually supporting the vendors (which incidentally are common to both the companies),” he added.
When asked if the pandemic has also affected the company’s new model development, Uchida replied in the negative.
“We cannot delay new model development because it will increase our model development cost. So we are going to go ahead with the original plan. There is no holdback on our product plans because of the COVID-19 situation. All our product plans are on course,” he said.
